U.S. FDA Drug Master File (DMF) Type III Packaging Submission Guide
Interpreting FDA guidelines for Type III Packaging DMFs, covering synthetic formulation secrecy, LOA requests, and annual maintenance.
U.S. FDA packaging registrations are filed as Type III DMFs. It allows packaging manufacturers to submit proprietary resin grades, pigment formulas, and manufacturing steps directly to the FDA database. Exporters issue a Letter of Authorization (LOA) to drug customers, keeping formulation details secret. Annual reports must be filed on the anniversary date to maintain active status.
Mandatory Technical Formula Details in Type III DMF
FDA reviewers check material chemical safety profiles; generic trade names are insufficient.
- Resin integrity: polymer chemical name, trade grade, manufacturer, and food contact status
- Additive disclosure: CAS numbers, structural formulas, and max concentration of colorants, plasticizers, slip agents
- Specifications: characteristic absorption wave bands in FTIR scans for batch-to-batch comparisons
FAQ
Does the FDA issue an approval certificate for Packaging DMFs?+
No. The FDA applies a passive review policy for DMFs. Upon submission, it is assigned a number and archived as active. Technical review is triggered only when a drug client references the DMF in their ANDA/NDA filing.
Next steps
If this topic applies to your product, facility, or supply chain requirement, start by confirming the target market, customer-required standard, existing documents, audit history, and expected timeline.
